Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 77 publications
Reply to "Does disease ontogeny matter more than JAK2 mutation status in acute myeloid leukemia?"
Journal: Cancer
Published: July 22, 2026
The Prognostic Utility of Normal Karyotype Fraction in Acute Myeloid Leukemia.
Journal: Clinical lymphoma, myeloma & leukemia
Published: June 11, 2026
Is there a best frontline therapy in chronic myeloid leukemia?
Journal: Haematologica
Published: July 13, 2025
Comparative Outcomes of Intensive Chemotherapy Versus Venetoclax Plus Hypomethylating Agents in Acute Myeloid Leukemia Patients Aged 60-75 Years: A Propensity Score-Adjusted Cohort Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: June 21, 2025
Impact of Cytogenetic Response to Therapy on Long-Term Survival in Acute Myeloid Leukemia.
Journal: American journal of hematology
Published: May 19, 2025
Comparing Outcomes of First-Line Intensive Chemotherapeutic Regimens in Adult Patients With Acute Lymphoblastic Leukemia at a Tertiary Center.
Journal: Clinical lymphoma, myeloma & leukemia
Published: April 20, 2025
Impact of TP53 mutation on survival outcomes in acute lymphoblastic leukemia at a tertiary center.
Journal: Leukemia & lymphoma
Published: April 09, 2025
Combining drugs that bypass p53 to treat TP53-mutated leukemias.
Journal: Blood advances
Published: March 31, 2025
EPR25-121: Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Cancer Patients: Testing and Referral Guidelines.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 28, 2025
Hypomethylating Agent and Venetoclax Combination Is a Safe and Effective Alternative to Intensive Chemotherapy in Older (≥ 70 Years) Patients With Newly Diagnosed Favorable Risk Acute Myeloid Leukemia.
Journal: American journal of hematology
Published: March 21, 2025
Last Updated: 09/26/2026